Undervalued Small-Cap Healthcare Stocks on NYS July 2024

July 04, 2024

Healthcare Sector

The healthcare sector includes companies in biotechnology, pharmaceuticals, hospitals, home and long-term care. It also includes related medical equipment manufacturers and suppliers.

New York Stock Exchange

The New York Stock Exchange, located in New York City, is the largest securities exchange in the world by market capitalization of its listed companies.

Our Valuation

A stock is considered undervalued if it trades at a discount to our valuation. To determine a stock’s intrinsic value, we developed an algorithm that uses 6 valuation models to determine the value of a company.* To learn more about stockcalc’s valuation methods, click here.

Undervalued Healthcare stocks

Stocks in this category are held primarily for potential income and capital appreciation.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose Price ($)Valuation ($)Difference (%)Average Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
A Agilent Technologies - - 0.00 - 0 0.74 29.9
ABBV AbbVie - - 0.00 - 0 3.70 48.8
ABT Abbott Laboratories - - 0.00 - 0 2.07 31.9
ADCT ADC Therapeutics - - 0.00 - 0 0.00 0.0
AGL Agilon Health - - 0.00 - 0 0.00 0.0
ALC Alcon - - 0.00 - 0 0.30 41.8
ALUR Allurion Technologies - - 0.00 - 0 0.00 0.0
AMN AMN Healthcare Services - - 0.00 - 0 0.00 13.0
AMWL American Well - - 0.00 - 0 0.00 0.0
ANRO Alto Neuroscience - - 0.00 - 0 0.00 0.0
All data provided as at market close July 02, 2024.

Company Details

Agilent Technologies

A:NYS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

29.9

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab (consisting of consumables and services related to life science and applied tools), and diagnostics and genomics.

Access the stockcalc valuation


AbbVie

ABBV:NYS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

48.8

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

Access the stockcalc valuation


Abbott Laboratories

ABT:NYS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

31.9

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment.

Access the stockcalc valuation


ADC Therapeutics

ADCT:NYS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

0.0

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

Agilon Health

AGL:NYS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

0.0

Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.

Access the stockcalc valuation


Alcon

ALC:NYS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

41.8

Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls one fourth of the U.S. contact lens market.

Access the stockcalc valuation


Allurion Technologies

ALUR:NYS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

0.0

Allurion Technologies Inc is a medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS.

Access the stockcalc valuation


AMN Healthcare Services

AMN:NYS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

13.0

AMN Healthcare Services is one of the largest healthcare staffing company in the United States. In 2023, it offered more than 13,000 nurses and allied healthcare full-time workers with provider clients nationwide. About two thirds of its business is generated from its temporary nursing division; the other third is generated from its physician placement and technology-backed workplace solutions divisions.

Access the stockcalc valuation


American Well

AMWL:NYS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

0.0

American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital.

Access the stockcalc valuation


Alto Neuroscience

ANRO:NYS

Close Price

-

Our Valuation

-

% Difference

0.00

Market Cap ($M)

0

P/E Ratio

0.0

Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
Agilent Technologies and AbbVie are the most undervalued Small-Cap Healthcare stocks on the NYS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-small-cap-healthcare-stocks-nys-july-2024
Agilent Technologies $A and AbbVie $ABBV are the most undervalued Healthcare stocks on the #NYS. See the full list: https://www.stockcalc.com/Blog/undervalued-small-cap-healthcare-stocks-nys-july-2024
Agilent Technologies and AbbVie are the most undervalued Small-Cap Healthcare stocks on the NYS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-small-cap-healthcare-stocks-nys-july-2024

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.